Literature DB >> 11834688

Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome.

Ioana R Preston1, James R Klinger, Jeanne Houtchens, David Nelson, Sangeeta Mehta, Nicholas S Hill.   

Abstract

Pulmonary arterial hypertension (PAH) is commonly associated with the CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome. Inhaled nitric oxide (iNO) is often used to assess acute vasoresponsiveness in patients with PAH, and reports of adverse reactions have been infrequent. We describe two of nine patients with PAH and CREST syndrome who had pulmonary edema develop during acute iNO testing. This complication was not encountered in the 46 patients with other forms of PAH tested with iNO. We suggest that iNO should be used with caution, if at all, to test acute vasoreactivity in patients with CREST syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834688     DOI: 10.1378/chest.121.2.656

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Persistent rash on the face and lips.

Authors:  Aaron Samsula; M Alan Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-10

2.  Vaso reactivity test using inhaled nitric oxide for pulmonary arterial hypertension accompanied by severe interstitial lung disease attributed to systemic sclerosis: A case report.

Authors:  Tomohiro Yamaguchi; Yasuhiro Izumiya; Ou Hayashi; Hiroya Hayashi; Mana Ogawa; Atsushi Shibata; Takanori Yamazaki; Minoru Yoshiyama
Journal:  J Cardiol Cases       Date:  2021-08-31

3.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

4.  Nitric oxide-associated pulmonary edema in children with pulmonary venous hypertension.

Authors:  J Scott Baird; Vinod Havalad; Linda Aponte-Patel; Thyyar M Ravindranath; Tessie W October; Thomas J Starc; Arthur J Smerling
Journal:  Pediatr Cardiol       Date:  2012-10-13       Impact factor: 1.655

Review 5.  Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.

Authors:  Bhavadharini Ramu; Thenappan Thenappan
Journal:  Curr Heart Fail Rep       Date:  2016-04

Review 6.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 7.  The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension.

Authors:  Evangelos D Michelakis
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

8.  Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome.

Authors:  Kimikazu Takeuchi; Kazuhiko Nakayama; Mitsumasa Okano; Naoki Tamada; Hideya Suehiro; Yuto Shinkura; Kenichi Yanaka; Hiroyuki Onishi; Hidekazu Tanaka; Toshiro Shinke; Noriaki Emoto; Ken-Ichi Hirata
Journal:  Respir Med Case Rep       Date:  2017-12-07

9.  Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Kari E Roberts; Archan M Shah; Shilpa A Desouza; William Howard; John Brennan; Nicholas S Hill
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.